Journal Scan

Aspirin Use Associated with Reduced Risk of Colorectal Cancers

Posted on May 21, 2020

Taking aspirin regularly potentially reduces the risk for several digestive tract cancers, including rare ones, according to a meta-analysis published in Annals of Oncology.

This systematic review and meta-analysis analyzed data from published observational studies on aspirin and cancers of the digestive tract sites.

Using random-effects models researched estimated the pooled relative risk (RR) of cancer for regular aspirin use versus non-use.

Patients who regularly took aspirin were at a reduced risk of colorectal cancer, squamous-cell esophageal cancer, adenocarcinoma of the esophagus and gastric cardia, stomach cancer, hepato-biliary tract cancer, and pancreatic cancer. Sex, location, and other selected covariates did not appear to impact risk estimates.

For colorectal cancer, taking aspirin between 75 mg-100 mg per day conveys a risk reduction of 10% and a dose of 325 mg per day conveys a risk reduction of 35%.


Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol. 2020;31(5):558‐568.